The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
-
BUSINESS Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
-
REGULATORY Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
-
BUSINESS Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
-
REGULATORY Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
-
BUSINESS INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
-
BUSINESS 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
-
REGULATORY Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
-
REGULATORY Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
-
BUSINESS Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
-
REGULATORY MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
-
REGULATORY Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
-
COMMENTARY Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
-
INTERVIEW Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
March 6, 2017
-
BUSINESS Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
-
REGULATORY 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
-
ORGANIZATION EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
-
INTERVIEW Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
February 28, 2017
-
BUSINESS Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
-
INTERVIEW Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…